Immune Checkpoint Marker of Programmed Death Ligand-1 (PD-L1) Expression in Surgical Lung Cancer Specimens
DOI:
https://doi.org/10.36497/jri.v42i2.286Keywords:
non small cell lung cancer, PD-L1 expression, polyclonal antibodyAbstract
Background: Currently immune checkpoint pathways of PD1-PD-L1 is being used to treat lung cancer and PD-L1 served as predictive biomarker. Investigations of PD-L1 expression as a target immunotherapy in lung cancer specimens in Indonesia is needed. This study aimed to evaluate PD-L1 expression in resected lung cancer specimens using immunohistochemistry techniques.
Methods: Thirty surgically resected sample from lung cancer patients were obtained. The whole specimens were stained by using immunohistochemistry techniques automatically in BOND-MAX Autostainner (Leica, Germany). PD-L1 polyclonal antibody (Genetex) at 1:1500 dilution was applied to immunohistochemistry staining procedure. Clinicopathological characteristic were acquired from the hospital registry database.
Result: A total of 30 surgical specimens were assessed from lung cancer patients. Twenty-four (80%) of them were Adenocarcinoma (AC), 1 (3, 33%) Adenosquamous carcinoma, 2 (6, 67%) were Squamous Cell Carcinoma (SSC), 1 (3, 33%) were Large Cell Carcinoma, 1 (3, 33%) were Neuroendocrine Carcinoma, 1 (3, 33%) were Adenoid Cyctic Carcinoma. The expression of PDL-1 positive reactivity was 16 of 30 (53.3%) specimens and we categorized into strong positivity (>50%), medium (= 50%) and low positivity (<50) from 21 specimens, 0 specimens and 7 specimens respectively.
Conclusion: PD-L1 expression could be detected in lung cancer specimen using polyclonal antibody.Downloads
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN: 2012. Int J Cancer. 2015;136:359-86.
Siegel RL, Miller KD, Jemal A. Cancer sratistics. CA Cancer J Clin. 2016;66:7-30.
Rafemanesh H, Mehtarpour M, Khani F, Hesami SM, Shamlou R, Towhidi F, et al. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis. 2016; 8(6):1094-102. doi: 10.21037/ jtd.2016.03.91.
Kerr and Nicolson. PD-L1 testing in NSCLC. Arch Pathol Lab Med. 2016;140:249 –54.
Janzic U, Kern I, Janzic A, Cavka L, Cufer T. PD-L1 Expression in squamous cell carcinoma and adenocarcinoma of the lung. Radiol Oncol. 2017;51(3):357 – 62.
Grigg C, Nayer A. PD-1 Biomarker testing for non- small cell lung cancer: truth or fiction. Biomed Central. 2016; 4(48):1-10.
Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12 (4): 252 – 64.
Tsao MS, Kerr KM, Dacic S, Yatabe Y, Hirsch F.R. editors. IASLC Atlas of PD-L1 Immunohistochemistry testing in lung cancer, 1st edition 2017. International Association for the Study of Lung Cancer, Aurora, USA.
Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcome. Onco target and therapy. 2016; 9: 5023 – 39.
Kluger H.M, Zito C.R, Turcu G, Baine M.K, Zhang H, Adeniran A, et al. PDL-1 studies across tumor types, its differential expression and predictive values in patients treated with immune checkpoint inhibitor. Clin Cancer Res. 2017; 23(15):4270-9.
Fredy R, Zhang Y, Ballas M, Shiddiqui M, Gupta P. PD-L1 expression in advance NSCLC: Insight into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112: 200 – 15.
Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964-75.
Teixido C, Karachaliou N, Gonzales M, Morales D, Roseli R. Assay for predicting and monitoring responses o lung cancer immunotherapy. Cancer Biol Med. 2015;12: 87 – 95.
Downloads
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
